Panacea Biotec Share Price Today (PANACEABIO)
TODAY IN ONE LINE
PANACEABIO slumped 5.9% on light volume, lagging Nifty's -0.8% move, supported by recent strong earnings.
With a market cap of ₹2,858.57 Cr., it trades at a P/E of -561.99. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
Panacea Biotec flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●Quarterly OutperformanceLatest quarter Sales up 25.8% and Profit up 93.0%
- ●High Promoter HoldingPromoters hold 72.5% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 12.2% YoY
- ●Rising Receivables vs SalesReceivables grew 24.2% outpacing sales growth of -0.0%
Latest Panacea Biotec News
What changed recently?
Recent events, corporate actions, and announcements.
Panacea Biotec Limited valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for Panacea Biotec Limited, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
Panacea Biotec Limited technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for Panacea Biotec Limited — derived from the live tape, not yesterday's close.
Panacea Biotec Limited last traded at ₹465 with an intraday range of ₹450.3–₹504.5 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹465.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 604.63 | +139.63 | +30.03% |
| R3 | 550.43 | +85.43 | +18.37% |
| R2 | 527.47 | +62.47 | +13.43% |
| R1 | 496.23 | +31.23 | +6.72% |
| PIVOT | 473.27 | 8.27 | 1.78% |
| CURRENT | 465.00 | — | — |
| S1 | 442.03 | -22.97 | -4.94% |
| S2 | 419.07 | -45.93 | -9.88% |
| S3 | 387.83 | -77.17 | -16.59% |
| S4 | 333.63 | -131.37 | -28.25% |
PANACEABIO is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹463.5–₹504.5
Trading Below opening range, showing Bearishness
Panacea Biotec Limited financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for Panacea Biotec Limited — consolidated or standalone — with margins, YoY growth and key ratios inline.
Panacea Biotec Limited reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹2,858.57 Cr. and reported EPS of ₹-0.94.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 559 | 640 ▲ 14.4% |
| Sales Growth YoY %Derived | -0.01% | 14.43% |
| Other Income | 21 | 17 ▼ 18.2% |
| Total Income | 580 | 657 ▲ 13.3% |
| 200 | 280 ▲ 40.6% | |
| Gross ProfitDerived | 360 | 359 ▼ 0.1% |
| Gross Margin %Derived | 64.31% | 56.16% |
| 385 | 364 ▼ 5.6% | |
| EBITDA (Operating Profit)Derived | -26 | -5 ▲ 82.0% |
| OPM %Derived | -4.63% | -0.73% |
| 75 | 59 ▼ 21.5% | |
| Profit Before Tax (PBT) | -8 | -7 ▲ 7.3% |
| 1 | -0 ▼ 127.3% | |
| Effective Tax %Derived | -9.69% | 2.85% |
| Profit/Loss from Discontinued Ops | — | — |
| Total Profit for Period | -9 | -7 ▲ 17.9% |
| Less: Non-controlling Interests | -0 | -2 ▼ 411.4% |
| Net Profit (Owner's PAT)Derived | -8 | -5 ▲ 35.8% |
| Net Profit Margin %Derived | -1.50% | -0.84% |
| PAT Growth YoY %Derived | -615.38% | 35.84% |
| Earnings Per Share (EPS ₹) | -1.37 | -0.88 ▲ 35.8% |
| Diluted Shares Outstanding (Cr) | 6 | 6 ▲ 0.0% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | 1 | 5 ▲ 388.3% |
| Total Expenses (incl. D&A & Interest) | 588 | 664 ▲ 13.0% |
| Material Cost % of RevenueDerived | 38.29% | 45.37% |
| Employee Cost % of RevenueDerived | 30.95% | 28.26% |
| Other Cost % of RevenueDerived | 37.99% | 28.63% |
| Interest Coverage (x)Derived | -15.65x | -6.23x |
| Period | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 544 | 625 ▲ 14.8% | 661 ▲ 5.8% | 460 ▼ 30.4% | 559 ▲ 21.6% | 559 ▼ 0.0% | 640 ▲ 14.4% | |
| Sales Growth YoY %Derived | — | 14.84% | 5.83% | -30.44% | 21.57% | -0.01% | 14.43% | |
| Other Income | 30 | 10 ▼ 66.4% | 11 ▲ 9.9% | 52 ▲ 370.9% | 26 ▼ 50.1% | 21 ▼ 19.9% | 17 ▼ 18.2% | |
| Total Income | 574 | 635 ▲ 10.6% | 672 ▲ 5.9% | 512 ▼ 23.9% | 585 ▲ 14.3% | 580 ▼ 0.9% | 657 ▲ 13.3% | |
157 | 205 ▲ 30.5% | 262 ▲ 28.1% | 253 ▼ 3.6% | 230 ▼ 8.9% | 200 ▼ 13.3% | 280 ▲ 40.6% | ||
| Gross ProfitDerived | 387 | 420 ▲ 8.5% | 399 ▼ 5.0% | 207 ▼ 48.1% | 329 ▲ 58.7% | 360 ▲ 9.3% | 359 ▼ 0.1% | |
| Gross Margin %Derived | 71.18% | 67.25% | 60.35% | 45.07% | 58.85% | 64.31% | 56.16% | |
356 | 344 ▼ 3.5% | 413 ▲ 20.2% | 305 ▼ 26.1% | 349 ▲ 14.4% | 385 ▲ 10.4% | 364 ▼ 5.6% | ||
| EBITDA (Operating Profit)Derived | 31 | 77 ▲ 144.4% | -14 ▼ 118.1% | -98 ▼ 606.8% | -20 ▲ 79.5% | -26 ▼ 29.2% | -5 ▲ 82.0% | |
| OPM %Derived | 5.76% | 12.27% | -2.10% | -21.30% | -3.59% | -4.63% | -0.73% | |
202 | 231 ▲ 14.4% | 1,901 ▲ 723.0% | 146 ▼ 92.3% | 76 ▼ 47.8% | 75 ▼ 2.1% | 59 ▼ 21.5% | ||
| Profit Before Tax (PBT) | -172 | -144 ▲ 15.9% | 1,449 ▲ 1103.9% | 13 ▼ 99.1% | 1 ▼ 88.4% | -8 ▼ 637.2% | -7 ▲ 7.3% | |
17 | 2 ▼ 88.2% | 371 ▲ 18824.0% | 47 ▼ 87.4% | 3 ▼ 93.6% | 1 ▼ 74.2% | -0 ▼ 127.3% | ||
| Effective Tax %Derived | -9.70% | -1.36% | 25.60% | 363.67% | 201.35% | -9.69% | 2.85% | |
| Profit/Loss from Discontinued Ops | -6 | -1 ▲ 77.4% | — ▲ 100.0% | — | — | — | — | |
| Total Profit for Period | -188 | -146 ▲ 22.2% | 1,078 ▲ 837.3% | -34 ▼ 103.1% | -2 ▲ 95.6% | -9 ▼ 481.3% | -7 ▲ 17.9% | |
| Less: Non-controlling Interests | — | — | — | — | -0 | -0 ▼ 6.1% | -2 ▼ 411.4% | |
| Net Profit (Owner's PAT)Derived | -188 | -146 ▲ 22.2% | 1,078 ▲ 837.3% | -34 ▼ 103.1% | -1 ▲ 96.5% | -8 ▼ 615.4% | -5 ▲ 35.8% | |
| Net Profit Margin %Derived | -34.53% | -23.40% | 163.02% | -7.34% | -0.21% | -1.50% | -0.84% | |
| PAT Growth YoY %Derived | — | 22.18% | 837.28% | -103.13% | 96.53% | -615.38% | 35.84% | |
| Earnings Per Share (EPS ₹) | -31.72 | -24.11 ▲ 24.0% | 175.98 ▲ 829.9% | -5.51 ▼ 103.1% | -0.19 ▲ 96.6% | -1.37 ▼ 621.1% | -0.88 ▲ 35.8% | |
| Diluted Shares Outstanding (Cr) | 6 | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 0.0% | 6 ▲ 0.0% | |
| Share of Profit from Associates/JVs | 0 | 0 ▼ 75.8% | — ▼ 100.0% | — | — | — | — | |
| Other Comprehensive Income (Net of Tax) | 3 | 1 ▼ 70.2% | -0 ▼ 148.8% | 0 ▲ 170.0% | -0 ▼ 239.3% | 1 ▲ 384.6% | 5 ▲ 388.3% | |
| Total Expenses (incl. D&A & Interest) | 745 | 779 ▲ 4.5% | -777 ▼ 199.7% | 499 ▲ 164.2% | 583 ▲ 17.0% | 588 ▲ 0.7% | 664 ▲ 13.0% | |
| Material Cost % of RevenueDerived | 32.96% | 26.96% | 42.53% | 45.88% | 37.64% | 38.29% | 45.37% | |
| Employee Cost % of RevenueDerived | 26.16% | 24.99% | 27.67% | 27.50% | 26.75% | 30.95% | 28.26% | |
| Other Cost % of RevenueDerived | 39.26% | 29.99% | 34.78% | 38.87% | 35.69% | 37.99% | 28.63% | |
| Interest Coverage (x)Derived | -0.07x | 0.17x | -0.32x | -30.87x | -15.86x | -15.65x | -6.23x |
Panacea Biotec segment analysis : revenue and profit mix.
Disclosed business segments at Panacea Biotec with their share of revenue and profit, switchable between consolidated and standalone reporting.
Panacea Biotec discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for Panacea Biotec Limited.
Our AI distills the core fundamental drivers supporting Panacea Biotec Limited, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
Panacea Biotec Limited's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
High promoter holding of 72.48% ensures strong insider alignment and governance stability
Quarterly revenue surged 25.80% YoY, demonstrating robust near-term demand momentum
Low debt-to-equity ratio of 0.0003 indicates minimal financial leverage and strong resilience
Diversified product portfolio across vaccines, formulations, and nutraceuticals reduces concentration risk
Operating cash flow positive at ₹3.94 Cr in FY25, showing improving liquidity trajectory
Key Risks.
Operating margin of -0.73% signals acute core profitability challenges and pricing pressure
Latest quarterly EPS declined 12.2% TTM despite revenue growth, indicating severe margin compression
Consistent net losses with negative ROE of -2.36% undermine shareholder value creation
Free cash flow persistently negative across all periods, limiting reinvestment and dividend capacity
Market cap of ₹3,029.16 Cr dwarfs peers like Cipla, creating significant scale disadvantage
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Panacea Biotec Limited peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — Panacea Biotec Limited is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
Panacea Biotec Limited chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for Panacea Biotec Limited — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
- 1Pick how to scan. Detection sets sensitivity — Daily (standard) → Weekly (big swings). History sets how far back to look.
- 2Read the summary. The tiles at the top give the current read: net bias, the strongest pattern, and the one nearest to triggering.
- 3Scan the list. Use the Actionable, Watchlist, and History tabs to browse patterns. Click a pattern card to focus it.
- 4Inspect on the chart. Focusing draws the pattern’s pivots plus its break (blue), target (amber) and invalidation lines.
- 5Filter to what matters. Use the status controls (Confirmed, Forming, Invalidated) to hide noise and find exactly what you are looking for.
Pattern history — every completed pattern and its outcome
Panacea Biotec Limited delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for Panacea Biotec Limited over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in Panacea Biotec Limited stood at 41.5% of traded volume, against a 20-day average of 35.6%.
Panacea Biotec announcements: results, concalls, ratings, M&A.
Filings Panacea Biotec sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
Panacea Biotec files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 82 documents below.
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Updates
Panacea Biotec Limited has informed the Exchange regarding 'Details of Shares dematerialized during June 2026'.
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Panacea Biotec Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Panacea Biotec Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
Trading Window
Panacea Biotec Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations,…
Panacea Biotec dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue Panacea Biotec has declared, sequenced by announce and record date.
Panacea Biotec corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
Panacea Biotec insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in Panacea Biotec as reported to SEBI — buying and selling signals from the people who know the business best.
Panacea Biotec insider activity below tracks 7 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Sandeep Jain | Insider | 31 Dec 2024 | sell | −5.0 K | ₹20.45 L | ₹409.07 |
| Sandeep Jain | Insider | 30 Dec 2024 | sell | −10.0 K | ₹42.5 L | ₹425.04 |
| Rajesh Jain | Insider | 26 Dec 2024 | buy | +3.0 K | ₹13.65 L | ₹454.90 |
| Sandeep Jain | Insider | 24 Dec 2024 | sell | −5.0 K | ₹21.31 L | ₹426.23 |
| Sandeep Jain | Insider | 23 Dec 2024 | sell | −10.0 K | ₹43.96 L | ₹439.55 |
| Sandeep Jain | Insider | 19 Dec 2024 | sell | −5.0 K | ₹22.54 L | ₹450.89 |
| Sandeep Jain | Insider | 18 Dec 2024 | sell | −5.7 K | ₹25.95 L | ₹455.32 |
About Panacea Biotec Limited: business, sector, key facts.
What Panacea Biotec Limited does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
Panacea Biotec Limited operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: PANACEABIO, BSE: 531349.
Panacea Biotec Limited is a multinational biotechnology company headquartered in New Delhi, India, established in 1984. Its core business focuses on the research, development, manufacturing, and marketing of a diverse range of healthcare products across various sectors. This encompasses a substantial portfolio spanning vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products, showcasing a vertically integrated approach to the healthcare market.
The company operates through two primary segments: Vaccines and Formulations. The Vaccines segment includes a wide array of vaccines targeting various diseases such as typhoid, pneumococcal infections, dengue fever, hepatitis A, and varicella (chickenpox). They also hold significant partnerships, such as their collaboration with the Russian Direct Investment Fund for the production of the Sputnik V COVID-19 vaccine. This demonstrates their capacity for large-scale vaccine production and global collaborations.
The Formulations segment encompasses a broad spectrum of prescription pharmaceuticals. These medications address a wide array of therapeutic areas including transplantation, renal disease, oncology, respiratory illnesses, pain management, diabetes, cardiovascular diseases, gastrointestinal issues, nephrology, osteoporosis, and orthopedics. This diversified portfolio demonstrates their commitment to providing treatment options across a wide range of medical needs.
Beyond pharmaceuticals and vaccines, Panacea Biotec also manufactures and markets nutraceuticals and pediatric nutrition products under the ChilRunFull, ChilRun 7+, and ChillRun No Sucrose brands. This expansion into the health supplement and nutritional market showcases a strategic move to cater to broader health and wellness needs.
The company's international reach is significant, with exports to approximately 50 countries. Furthermore, Panacea Biotec has established key collaborations with various entities including Natco Pharma Ltd. and Breckenridge Pharmaceutical Inc. for the manufacture and supply of Azacitidine injection, and the Indian Council of Medical Research for clinical trials of the DengiAll vaccine. This highlights their involvement in both international and domestic research and development collaborations.
In addition to its core healthcare businesses, Panacea Biotec also participates in the real estate sector, though the extent of this involvement is not specified in the provided information. Overall, Panacea Biotec presents a multifaceted biotechnology company with a strong presence in India and a growing international footprint, focusing on a diverse array of healthcare solutions.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs and Pharmaceuticals (AKUMS) Share PricePeer
- Top Losers TodayScreener
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about Panacea Biotec Limited (PANACEABIO).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of Panacea Biotec Limited (PANACEABIO)?
The current share price of Panacea Biotec Limited (PANACEABIO) is ₹465. Today, the stock has declined by ₹29.00 (5.87%), trading in a range of ₹450.3 to ₹504.5. The stock opened at ₹486 with a trading volume of 6,14,596 shares.
02Is Panacea Biotec Limited stock a good investment for long-term?
Panacea Biotec Limited can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,858.57 crores, P/E ratio of -561.99, ROE of -2.36%, and ROCE of -2.44%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of Panacea Biotec Limited stock?
The 52-week high price of Panacea Biotec Limited (PANACEABIO) is ₹647, while the 52-week low is ₹292.4. Currently trading at ₹465, the stock is 48.7% away from its 52-week low and 28.1% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy Panacea Biotec Limited stock at the current price?
Whether to buy Panacea Biotec Limited stock at ₹465 depends on multiple factors. The stock is currently trading with a P/E ratio of -561.99 and P/B ratio of 3.63. Today's performance shows a loss of 5.87%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of Panacea Biotec Limited and when is the next dividend?
Panacea Biotec Limited offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹465, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of Panacea Biotec Limited?
Panacea Biotec Limited's key financial metrics include: P/E Ratio: -561.99, P/B Ratio: 3.63, ROE: -2.36%, ROCE: -2.44%, Dividend Yield: 0.00%, EPS: ₹-0.94, Book Value: ₹128.44, and Debt-to-Equity: 0.03. The company's market cap stands at ₹2,858.57 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is Panacea Biotec Limited stock performing today in the market?
Panacea Biotec Limited stock opened at ₹486 and is currently trading at ₹465, showing a decline of ₹29.00 (5.87%). The intraday high is ₹504.5 and low is ₹450.3. The trading volume stands at 6,14,596 shares, indicating moderate market participation today.
08What is the P/E ratio of Panacea Biotec Limited and what does it indicate?
Panacea Biotec Limited has a Price-to-Earnings (P/E) ratio of -561.99, which means investors are willing to pay ₹-561.99 for every ₹1 of earnings. With an EPS of ₹-0.94, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about Panacea Biotec Limited (PANACEABIO) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.